Fig. 3

Connectivity map analysis and drug repurposing to AD therapy. a Schematic representation of connectivity map analysis: differentially expressed targets of repressed or activated MR candidates, for each case-control study, were ranked and used as query signature to the connectivity map webtool against gene expression profiles database of several cell lines treated with thousands of FDA-approved compounds. b Case-control associated drugs: consensus drugs consistently matched with at least two case-control studies. Drugs with negative AD association are assumed with therapeutic potential, and the ones with positive association are considered AD mimetic. ns not significant